

RYAH Announces Key Promotions and New Hires

TORONTO, ON / ACCESSWIRE / June 1, 2022 / [RYAH GROUP](#) Inc. (CSE:RYAH or the "Corporation") is pleased to announce the appointments of [Jordan Medley](#) as Vice President of Global Product, [Sophie Kleshchuk](#) as Assistant Vice President of Global Operations, Ramon Torres as Senior Software Engineer, and [Harry Tetteh](#) as Research, Sales and Operations Associate.

C. Jordan Medley is a founding member of RYAH, since the inception of Potbotics Inc. in 2015, which RYAH Medtech Inc. merged with. Jordan was the human intelligence driving the patented artificial intelligence (AI) that underlies RYAH's big data ecosystem. He directed the majority of RYAH's IoT device hardware development and various medical device approval initiatives including Canada, New Zealand, and the EU (in progress). Jordan established successful manufacturing supply processes with key international partners, including UK clinical trial partner (LVL clinic) and French partner DelleD. Jordan earned a Bachelor of Science degree in Sports Management at Ithaca College, New York, and resides in the greater New York metropolitan area. Jordan is passionate about health and fitness and has a well-deserved reputation as a cannabis expert.

Sophie (Sofiya) Kleshchuk has served as a key member of the RYAH team, instrumental to the company's growth and operational excellence, since joining in 2019. Sophie has made major contributions to business development, stakeholder relationship management, and administrative governance of the Group and its subsidiaries. Previously, Sophie served in various business development, marketing, public relations, media management, and software development roles. She earned a Master's degree in International Communication and Global Media from Taras Shevchenko National University of Kyiv, Ukraine. In addition, Sophie was awarded a Certificate in Innovation and Entrepreneurship from the University of A Coruna, Spain. Sophie is also a former member of Ukrainian national swimming team and holds a national rank of Master of Sports.

Ramon Torres has been a major contributor to RYAH's technology development team for several years, and now joins as a regular employee. Ramon played a major role designing and building the back-end infrastructure that powers the data insights and analytics derived from RYAH's IoT-connected medically certified devices. With the expansion of his role, Ramon will continue to grow and enhance RYAH's data capture and AI capabilities to establish RYAH as the leading data pioneer in the industry. He holds a Bachelor of Science degree in Accounting and Information Technology from University of Puerto Rico. Ramon is based in Silicon Valley, CA.

Harry Tetteh joins RYAH Group as Research, Sales and Operations Associate, in which he will help identify and develop opportunities to expand into new markets and bring RYAH's vision to life. Harry brings over a decade of experience in enterprise technology sales with Oracle, and globally award-winning experience as an expert in global multimedia collaboration, winning the ThinkQuest International Competition operated by the Oracle Education Foundation in 2008. Harry's academic background includes a Master's of Science degree in Instructional and Educational Technology awarded by the National University (California), and an Innovation and

Entrepreneurship Certificate from Stanford University Graduate School of Business. Harry works and lives with his family in Fitchburg, Massachusetts.

About RYAH Group Inc.

RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its range of innovative IoT-connected medical devices including inhalers, patches, and pens. RYAH's robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant patient data, helping doctors and patients personalize treatments, control dosages, and better predict and monitor outcomes. Beyond specific medical uses, RYAH supports the use of a variety of nutraceuticals by users for wellness purposes, including personal enjoyment - i.e., recreational use. The collection and analyses of objective and subjective usage data, along with data derived through natural language processing of various scientific and other relevant literatures, will enable highly valuable insights for a wide variety of stakeholders, starting with the users themselves, and extending to clinicians, medical scientists, insurance providers, dispensaries, licensed growers, producers, pharmaceutical producers, and more. Through the above, a relentless focus on innovation, and track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable IP portfolio and big data assets ready to be monetized.

AI: Artificial Intelligence

IoT: Internet of Things

HIPAA: Health Insurance Portability and Accountability Act

IP: Intellectual Property

R&D: Research and Development

NFT: Non-Fungible Token

Disclaimers:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "in the process" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such

statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's on-going filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

For further information contact:

Dr. David R. Richards, CEO: drichards@ryah.com

+1.703.453.7170

Mr. François C. Desrosiers, CFO: fdesrosiers@ryah.com

+1.438-874-0558

SOURCE: RYAH Medtech Inc